Press releases
CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU for patients with triple class refractory multiple myeloma
June 23, 2022
STOCKHOLM — June 23, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today ann...
Annual General Meeting in Oncopeptides AB (publ)
May 25, 2022
STOCKHOLM — May 25, 2022 — The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given...
Oncopeptides publishes Q1 report 2022
May 4, 2022
STOCKHOLM — May 4, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publi...
Invitation to presentation of Q1 report
April 27, 2022
STOCKHOLM — April 27, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today an...
Oncopeptides publishes the 2021 Annual Report
April 21, 2022
STOCKHOLM — April 21, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today an...
Number of shares and votes in Oncopeptides
March 31, 2022
STOCKHOLM — March 31, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today an...
Oncopeptides publishes year-end report 2021
February 17, 2022
STOCKHOLM — February 17, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today publ...
Invitation to presentation of 2021 year-end results
February 14, 2022
STOCKHOLM — February 14, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on the development of therapies for difficult-to-treat hematological diseases, will publish i...
Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US – no intent to market in the US at this time
January 21, 2022
STOCKHOLM — January 21, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today ...
Oncopeptides phase 3 OCEAN study published in the Lancet Haematology
January 13, 2022
STOCKHOLM — January 13, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today ...
Oncopeptides announces year-end cash 2021
January 5, 2022
STOCKHOLM — January 5, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today a...